Coronavirus vaccine: Things to know about process, timeline & effectiveness

Sources revealed, data from the global trials would be submitted to the Indian regulator by the end of December

Topics
Coronavirus | Coronavirus Vaccine | Coronavirus Tests

Kanishka Gupta  |  New Delhi 

A healthcare worker prepares specimen collection tubes at a coronavirus disease (COVID-19) drive-thru testing location in Houston, Texas. Photo: Reuters
Photo: Reuters

After Pfizer and Moderna, the much anticipated AstraZeneca-Oxford vaccine candidate has shown positive results in an interim analysis of clinical trials in the UK and Brazil, with a vaccine efficacy of up to 90 per cent in different dosing regimens.

Sources revealed, data from the global trials would be submitted to the Indian regulator by the end of December, and Serum Institute of India (SII), AstraZeneca’s manufacturing partner here, would submit the interim data from the Indian arm by then.

Tune in for more Track Title by Scott Buckley – www.scottbuckley.com.au

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Coronavirus
First Published: Tue, November 24 2020. 13:45 IST
RECOMMENDED FOR YOU